Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

P4498

Sigma-Aldrich

Pravastatin sodium salt hydrate

≥98% (HPLC), powder

Synonyme(s) :

(βR, δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β, δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic acid sodium hydrate, Eptastatin sodium salt hydrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill) :
C23H35O7Na · xH2O
Numéro CAS:
81131-70-6
Poids moléculaire :
446.51 (anhydrous basis)
Numéro MDL:
MFCD00887601
Code UNSPSC :
12352200
ID de substance PubChem :
329820206
Nomenclature NACRES :
NA.77

Source biologique

synthetic (organic)

Essai

≥98% (HPLC)

Forme

powder

Couleur

white

Pf

171.2-173 °C

Solubilité

H2O: >10 mg/mL

Auteur

Bristol-Myers Squibb

Température de stockage

2-8°C

Chaîne SMILES 

[Na+].[H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@]12[H])C[C@@H](O)CC([O-])=O

InChI

1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1

Clé InChI

VWBQYTRBTXKKOG-IYNICTALSA-M

Informations sur le gène

human ... HMGCR(3156)

Description générale

Pravastatin sodium is an orally effective hypocholesterolaemic agent which is structurally similar to lovastatin and compactin.

Application

Pravastatin sodium salt hydrate has been used in the enzymatic method to measure mevalonic acid in serum.

Actions biochimiques/physiologiques

Competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Inhibits cholesterol synthesis in vivo (Ki ~1 nM).
Pravastatin sodium is a competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.

Caractéristiques et avantages

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000212710
0000186357
096M4760V
026M4715V

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Statins for treating stable angina: can statins improve the plaque morphology and angina?
Cheol Whan Lee et al.
Future cardiology, 9(2), 155-158 (2013-03-08)
Kevin F Erickson et al.
Journal of the American College of Cardiology, 61(12), 1250-1258 (2013-03-19)
The authors sought to evaluate the cost-effectiveness of statins for primary prevention of myocardial infarction (MI) and stroke in patients with chronic kidney disease (CKD). Patients with CKD have an elevated risk of MI and stroke. Although HMG Co-A reductase
S M Singhvi et al.
British journal of clinical pharmacology, 29(2), 239-243 (1990-02-01)
Pravastatin sodium, a competitive inhibitor of HMG-CoA reductase, is a new orally effective hypocholesterolaemic agent. In a two-way crossover study, eight healthy male subjects each received an intravenous and an oral dose of [14C]-pravastatin sodium. The oral absorption of [14C]
Wibo B van Scheppingen et al.
Molecules (Basel, Switzerland), 26(15) (2021-08-08)
Dihydro analogues are known byproducts of the fermentative production of statins and cannot be detected with existing pharmacopoeia analysis methods. We detected dihydropravastatin in most commercial formulations of pravastatin with LC-MS, in some cases in levels requiring identification. In fermentation
Tsuyoshi Nozue et al.
The American journal of cardiology, 111(11), 1570-1575 (2013-03-19)
A low n-3 to n-6 polyunsaturated fatty acid (PUFA) ratio is associated with cardiovascular events. However, the effects of this ratio on coronary atherosclerosis have not been fully examined, particularly in patients treated with different types of statins. This study
Afficher tous les articles scientifiques apparentés

Articles

Cholesterol Biosynthesis Regulation

Cholesterol synthesis regulation by dietary levels, LDL receptors control lipid-rich LDL particle transport in cells.

Cholesterol Biosynthesis Regulation

Cholesterol synthesis regulation by dietary levels, LDL receptors control lipid-rich LDL particle transport in cells.

Cholesterol Biosynthesis Regulation

Cholesterol synthesis regulation by dietary levels, LDL receptors control lipid-rich LDL particle transport in cells.

Cholesterol Biosynthesis Regulation

Cholesterol synthesis regulation by dietary levels, LDL receptors control lipid-rich LDL particle transport in cells.

Afficher tout

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique